How do tenascins influence the birth and life of a malignant cell?

被引:30
作者
Brellier, Florence [1 ]
Chiquet-Ehrismann, Ruth [1 ]
机构
[1] Novartis Res Fdn, Friedrich Miescher Inst Biomed Res, Basel, Switzerland
基金
瑞士国家科学基金会;
关键词
tenascin; genomic instability; stem cells; primary tumour; EMT; angiogenesis; extracellular matrix; metastasis; mechanical forces; cancer therapy; microenvironment; stroma; CARCINOMA-ASSOCIATED FIBROBLASTS; EXTRACELLULAR-MATRIX PROTEINS; HUMAN BREAST-CANCER; C EXPRESSION; GENE-EXPRESSION; STEM-CELLS; IN-VITRO; PANCREATIC-CANCER; TUMOR PROGRESSION; TRANSGENIC MICE;
D O I
10.1111/j.1582-4934.2011.01360.x
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Introduction Birth of a malignant cell Niches for self-renewable cells Expression patterns in tumours Promotion of tumour cell proliferation Promotion of tumour cell migration Contribution to epithelial-mesenchymal transition (EMT) Promotion of angiogenesis Promotion of metastasis How do tenascins signal to cells? Importance of the mechanical aspect Evasion of tumour cells from conventional therapy Conclusions Tenascins are large glycoproteins found in embryonic and adult extracellular matrices. Of the four family members, two have been shown to be overexpressed in the microenvironment of solid tumours: tenascin-C and tenascin-W. The regular presence of these proteins in tumours suggests a role in tumourigenesis, which has been investigated intensively for tenascin-C and recently for tenascin-W as well. In this review, we follow a malignant cell starting from its birth through its potential metastatic journey and describe how tenascin-C and tenascin-W contribute to these successive steps of tumourigenesis. We consider the importance of the mechanical aspect in tenascin signalling. Furthermore, we discuss studies describing tenascin-C as an important component of stem cell niches and present examples reporting its role in cancer therapy resistance. © 2011 The Authors Journal of Cellular and Molecular Medicine © 2011 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd.
引用
收藏
页码:32 / 40
页数:9
相关论文
共 99 条
  • [71] Stem cells, cancer, and cancer stem cells
    Reya, T
    Morrison, SJ
    Clarke, MF
    Weissman, IL
    [J]. NATURE, 2001, 414 (6859) : 105 - 111
  • [72] Dilfferential gene expression analysis reveals activation of growth promoting signaling pathways by tenascin-C
    Ruiz, C
    Huang, WT
    Hegi, ME
    Lange, K
    Hamou, MF
    Fluri, E
    Oakeley, EJ
    Chiquet-Ehrismann, R
    Orend, G
    [J]. CANCER RESEARCH, 2004, 64 (20) : 7377 - 7385
  • [73] Role of RhoA/ROCK-dependent actin contractility in the induction of tenascin-C by cyclic tensile strain
    Sarasa-Renedo, A
    Tunç-Civelek, V
    Chiquet, M
    [J]. EXPERIMENTAL CELL RESEARCH, 2006, 312 (08) : 1361 - 1370
  • [74] TENASCIN-C IN SERUM - A QUESTIONABLE TUMOR-MARKER
    SCHENK, S
    MUSER, J
    VOLLMER, G
    CHIQUETEHRISMANN, R
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1995, 61 (04) : 443 - 449
  • [75] Tenascin-W is found in malignant mammary tumors, promotes alpha8 integrin-dependent motility and requires p38MAPK activity for BMP-2 and TNF-alpha induced expression in vitro
    Scherberich, A
    Tucker, RP
    Degen, M
    Brown- Luedi, M
    Andres, AC
    Chiquet- Ehrismann, R
    [J]. ONCOGENE, 2005, 24 (09) : 1525 - 1532
  • [76] Murine tenascin-W: a novel mammalian tenascin expressed in kidney and at sites of bone and smooth muscle development
    Scherberich, A
    Tucker, RP
    Samandari, E
    Brown-Luedi, M
    Martin, D
    Chiquet-Ehrismann, R
    [J]. JOURNAL OF CELL SCIENCE, 2004, 117 (04) : 571 - 581
  • [77] Schliemann C, 2010, RECENT RESULTS CANC, V180, P201, DOI 10.1007/978-3-540-78281-0_12
  • [78] Shekhar MPV, 2001, CANCER RES, V61, P1320
  • [79] SRIRAMARAO P, 1993, J CELL SCI, V105, P1001
  • [80] Epidermal growth factor (EGF)-like repeats of human tenascin-C as ligands for EGF receptor
    Swindle, CS
    Tran, KT
    Johnson, TD
    Banerjee, P
    Mayes, AM
    Griffith, L
    Wells, A
    [J]. JOURNAL OF CELL BIOLOGY, 2001, 154 (02) : 459 - 468